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Concepts, Labeling Procedures, and Design
of Cell Proliferation Studies Relating to
Carcinogenesis
by Thomas L. Goldsworthy,1 Byron E. Butterworth,1 and
Robert R. Maronpot2
Chemicals may induce cell proliferation directly as mitogens or indirectly via cell death with
subsequent proliferation to replace lost cells. Chemically induced proliferation has been demon-
strated to play a role in the carcinogenic process. A wide range ofprocedures and techniques are
currently being used to define the quantitative relationship between the extent and duration of
chemically induced cell proliferation and carcinogenic potential in different species and target
organs. However, a limited database and nonstandard protocols and procedures for measuring
cell proliferation have made it difficult to compare results between laboratories. Comparison of
frequencies of S phase between control and treated animals is the most commonly used end
point in cell proliferation studies and may be regarded as an indirect indication of a prolifera-
tive response.This response can be ascertained as labeling indexes (LI; percentage of cells in S
phase) after the administration of the DNA precursor labels (tritiated thymidine; 3H-TdR; bro-
modeoxyuridine, BrdU) or through immunostaining of the endogenous cell replication marker,
proliferating cell nuclear antigen (PCNA). Both approaches are applicable to tissue sections. An
important issue in the design ofexperimental studies for measuring LI is determining how and
when to investigate proliferative responses in relation to the chemical treatment regimen.
Variables to consider when designing cell proliferation studies include the animal's age, chemi-
cal dose and method of treatment, choice and dose of label, time and length that the label is
administered, and methods of quantitation. Study design considerations depend on the experi-
mental objective. A common approach to characterize the complex relationship ofcell prolifera-
tion and carcinogenic activity has been to focus on relatively early (less than 90 days) prolifera-
tive responses in the target tissue. However, a larger database on the duration and nature ofthe
chemically induced proliferative response under bioassay conditions in the target cell popula-
tion is required to more clearly establish the role ofthis end point in the cancer process. In addi-
tion, studies must also investigate mitogenic versus cytotoxic induction of cell proliferation in
normal and preneoplastic cells and differential toxicity that may provide a preferential growth
advantage to spontaneous orchemically induced intermediate or malignant cells.
Introduction
Carcinogenesis is a complex process in which normal
cellular growth-control genes are altered by several,
possibly sequential, mutational events with subse-
'Chemical Industry Institute of Toxicology, Research Triangle
Park, NC 27709.
2National Institute of Environmental Health Sciences, P.O. Box
12233, Research Triangle Park, NC 27709.
Address reprint requests to T. L. Goldsworthy, Chemical Industry
Institute ofToxicology, P.O. Box 12137, Research Triangle Park, NC
27709.
This paper was presented at the Symposium on Cell Proliferation
and Chemical Carcinogenesis that was held January 14-16, 1992, in
Research Triangle Park, NC.
quent clonal proliferation ofthe resulting precancerous
or cancerous cells (1,2). Chemical carcinogens may act
by inducing mutations and/or altering cellular growth
control (3). For nongenotoxic carcinogens, the induc-
tion ofcell proliferation and its effects on the processes
of tumor initiation, promotion, and progression appear
to be important events in the formation of tumors (4).
Currently, there is a limited database for chemicals in
which induced proliferation has been measured over
time under bioassay conditions. The database assess-
ing cell turnover in the developing neoplastic lesions is
even more limited. A glossary of terms describing
processes related to chemically induced cell prolifera-
tion is presented in Table 1.
One class of chemical carcinogens is the genotoxi-
cants. These compounds or their metabolites interactGOLDSWORTHYETAL.
Table 1. Definitions ofterms
Term Definition
Apoptosis Physiological single-cell death
Bromodeoxyuridine Thymidine analog used as a labeling
(BrdU) agent in cell proliferation studies
Cell replication Production oftwo daughter cells by
the process ofreplicative DNA synthe-
sis and subsequent cell division
Cell turnover The steady-state rates ofcell replica-
tion and cell death in a tissue
Cytotoxicants Chemicals that cause cell degeneration
and/or cell death
Hyperplasia Increase in the size oftissue through
an increase in cell number
Hypertrophy Increase in the size ofa tissue through
an increase in cell size
Labeling index (LI) Percentage oflabeled cells
Mitogens Chemicals that induce hyperplasia
with no observable cytolethality
Mitotic index (MI) Percentage ofcells undergoing mitosis
Proliferating cell nuclear Endogenous cell cycle-related nuclear
antigen (PCNA) protein; auxiliary protein ofDNA poly-
merase 8
Pulse labeling Single administration ofa DNA pre-
cursor label
Pump labeling Continuous administration ofa DNA
precursor label via implantation ofan
osmotic pump
Regenerative proliferation Cell division induced to replace dead
cells
S phase Synthesis phase portion ofthe cell
cycle in which nuclear DNA is replicat-
ed. During S-phase, DNA precursors
such as 3H-TdR, and analogues such as
bromodeoxyuridine are incorporated
into the DNA
3H-TdR Radiolabeled DNA precursor; labeling
agent in cell proliferation studies
with DNA and induce mutations or chromosomal alter-
ations. The observation that most mutagens are also
carcinogens is the basis for many current predictive
assays and risk assessment models. However, there
are also various classes of carcinogens that do not
interact directly with DNA; these are frequently
referred to as nongenotoxic carcinogens. Subclasses of
nongenotoxic agents are mitogens and cytotoxicants.
For some nongenotoxic carcinogens, induction of cell
proliferation in target tissue appears to be associated
with cancer development (5). For mitogens and cyto-
toxicants, differential toxicity and/or growth stimula-
tion may provide a preferential growth advantage to
spontaneous or chemically induced initiated or malig-
nant cells. Mutagens are more effective carcinogens at
doses that also induce cell proliferation, and mutations
may occur secondary to increased cell turnover (4).
Thus, chemically induced cell proliferation may poten-
tiate the outcomes ofboth genotoxic and nongenotoxic
carcinogens and should be considered in risk assess-
ment (5).
Although cell replication is intricately involved in
the carcinogenic process, there are rapidly proliferat-
ing tissues in the body where cancer is rare. For exam-
ple, the spontaneous tumor frequency is low in the
small intestine, where cells proliferate at a very high
rate. In such cell populations, inherent mechanisms
must exist to repair genetic damage or eliminate
altered cells (i.e., cell death and/or differentiation)
before cancer progression can occur. The magnitude of
proliferation over that ofthe normally occurring cellu-
lar processes may be important in cancer development.
An increased number of critical processes, i.e., muta-
tions, may be required for the induction of cancer in
proliferating cell populations as compared to a lower
number of critical events in nonproliferating cells or
tissues. Thus, just as mutagenicity does not always
translate into carcinogenicity, not all chemically
induced cell proliferation leads to cancer.
Chemically Induced Cell
Proliferation
Chemically induced proliferative responses may be
classified as either mitogenic or cytotoxic. Increased
cell turnover may result through chemical interactions
with cellular receptors, growth factors, and growth
regulatory genes; by causing cell death and subsequent
regenerative growth; through interrupting tissue
growth control mechanisms such as cell-cell communi-
cation; and by inhibiting programmed cell death (apop-
tosis). Mitogens induce cell proliferation without any
detectable cell death, resulting in an increase in the
size ofthe target organ. In contrast, cytotoxicants pro-
duce necrosis that is often followed by reparative cell
proliferation. Sustained cell proliferation in normal
cells produced by a cytotoxicant may increase the fre-
quency of spontaneous mutations that yield neoplastic
cells. Growth factor signals regulating regeneration
may provide a preferential stimulation to precancerous
cells, although the relative proliferative effects ofcyto-
toxic agents on normal and initiated (preneoplastic) or
malignant cells have received little attention. Due to
the different effects of cytotoxicants and mitogenic
agents, their role in the carcinogenic process may be
different (5,6). A cytotoxicant may provide a selective
growth advantage to initiated cells by producing
greater cell death in normal cells relative to initiated
or neoplastic cells (7). The potential for carcinogenic
action related to cytotoxicants appears to be secondary
to the induced cytolethality and subsequent cell prolif-
eration. It has been suggested that, in the special case
ofthose nongenotoxic chemicals that induce regenera-
tive cell proliferation in the target organ secondary to
cytotoxicity, the potential for carcinogenic activity
may be decreased below exposures that do not induce
acytotoxic/proliferative response (6).
Carcinogenic effects and activity may be different
for mitogen-stimulated cell proliferation (5,8,9). Mito-
gens tend to induce a relatively short burst ofcell pro-
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liferation during chemically induced tissue growth
immediately after exposure; this response is followed
by a return of cell turnover rates in the normal tissue
to baseline levels. Organ size, however, may remain
elevated as long as the agent is administered, resulting
in an increased number of proliferating cells in which
to maintain the increased cell population. Although the
mechanism of action of mitogenic carcinogens is
unknown, these agents may provide a selective growth
advantage to precancerous cells via growth inhibition
of "normal" cells, inhibition of apoptosis in precancer-
ous cells, and/or selective proliferative stimulation (10-
13). Analysis ofchemically induced cell proliferation in
specific precancerous cell populations, i.e., hepatic foci,
is needed to better understand the effect of mitogens
on tumor development. Because mitogens may act via
cellular receptors, the dose-response issue may be a
consideration of the quantitative relationship between
receptor occupancy and the triggering of the associat-
ed response. Experience with various specific recep-
tor-mediated chemicals demonstrates that a range of
exceedingly low doses to very high doses are required
to elicit the same effective response. In the case of
these agents, tissue- and species-specific responses
must be related to carcinogenicity (14).
Labeling Procedures
Multiple procedures can be used to assay chemically
induced cell proliferation. The use of different proto-
cols and procedures makes it difficult to define quanti-
tatively the relationship between chemically induced
cell proliferation and carcinogenic potential in different
species and target organs. Variables ofconcern include
animal age and species; chemical dose; treatment pro-
tocol; choice oflabel, timing, dose and duration oflabel-
ing; and methods ofquantitation (15).
Comparison ofS-phase labeling indexes (LI) between
control and treated animals is the most commonly used
end point in cell proliferation studies. Because S phase
is obligatory to cell replication, its frequency is regard-
ed as an indicator of the cell proliferation response.
Chemically induced cell proliferation is typically
assessed after the administration of DNA precursor
labels (3H-TdR or BrdU) or through the analysis of
endogenous cell replication markers such as the prolif-
erating cell nuclear antigen (PCNA; Fig. 1). The ability
to detect chemically induced S phase in tissue sections
allows for determining proliferative responses in spe-
cific target cell populations and correlating these with
histopathological changes. Specific techniques for
labeling and suggested protocols have been reviewed
(15).
The most generally used precursor label for DNA
synthesis is 3H-TdR. Its widespread use in cell prolif-
eration studies is due to its availability in highly specif-
ic activity, its specific incorporation into DNA, and the
ease ofmeasuring by a variety oftechniques. Although
high doses of3H-TdR induce perturbations ofcell-cycle
DNA Synthetic
Phase (S)
Terminal
Differentiated
Cells (TD)
FIGURE 1. Cell cycle. Diagram depicting stages ofcell cycle. Multiple
control points exist throughout the cell cycle to regulate the entry
and progression ofthe cell in each of the specified stages. During
the DNA synthetic phase or S-phase part of the cell cycle, cells
synthesizing DNA and will incorporate a specific DNA precursor
label such as 3H-thymidine and BrdU, or show high expression of
proliferation cell nuclear antigen and endogenous cell replication
marker. The visualization of these labels and markers allows the
determination ofthe labeling index which is an indirect indication
ofthe cell proliferation response. Go, resting phase; G1 and G2, gap
phases in cell cycle between DNA synthetic phase and mitosis.
dynamics, low doses of3H-TdR do not appear to affect
cell proliferation analysis (16). The most commonly
used form of3H-TdR is labeled on the methyl group. In
rodent cell-proliferation studies, the typical prepara-
tions of methyl-3H-TdR would have specific activities
in the range of 25-90 Ci/mM and a concentration of 1
mCi/mL. 3H-TdR can be administered to rodents via
intraperitoneal injection for use in pulse-label experi-
ments or in osmotic pumps for use in continuous-label
studies. Histoautoradiographic techniques are used on
tissue sections to identify cells in S phase. Specific
technical factors, proper internal controls, and poten-
tial problems in the use of 3H-TdR and autoradiogra-
phy have been reviewed (16,17). A significant draw-
back in the use ofhistoautoradiography is the extended
autoradiographic exposure times. As an example, if a
rat had been given a 3H-TdR solution for 3 days via an
osmotic pump at 10 iCi/hr, the autoradiographic expo-
sure period for a liver section would range from 4 to 10
weeks.
BrdU is a thymidine analog that has been used in
place of 3H-TdR to label a variety of tissues in vivo.
BrdU-labeled DNA is visualized using immunohisto-
chemical techniques and is as sensitive as 3H-TdR for
determining chemically induced hepatic and renal cell
proliferation (18). Advantages of using BrdU are the
elimination ofthe containment problems inherent with
use ofa radioisotope and the rapid results available by
immunostaining that requires hours to days rather
than weeks. A disadvantage of the BrdU technique is
the lack of a definitive lower-end-cut-off for determin-
ing whether a cell is labeled or not. In practice, this
concern does not appear to be a significant limitation
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for determining LI because detection of BrdU-labeled
cells are relatively straightforward to recognize. A
greater concern is the recent report ofadverse effects of
BrdU (19), suggesting that BrdU may be toxic, result-
ing in an enhanced LI. Therefore, dose-related toxicity
should be determined for each specific target tissue and
experimental protocol before selecting the appropriate
methodology. For example, a concentration of greater
than 32 mg/mL of BrdU in a 6-day osmotic pump
implanted in untreated control rats (10 UL/hr, 150-250 g
rat) and mice (1 guL/hr, 18-25 g mouse) was found to
increase the hepatocyte cell proliferation response, pre-
sumably due to BrdU-induced toxicity (20).
Recently, several monoclonal antibodies to endoge-
nous cell-cycle-related nuclear proteins have been
developed that can be used to preferentially identify
proliferating cells (21). PCNA, with peak concentra-
tions seen in the nucleus in late G1/S phase, may prove
to be one of the most versatile marker proteins
because it obviates administration ofthe label and may
be used to detect proliferating cells in both fixed
embedded tissues, and in frozen tissue samples (22).
Immunohistochemical methods for detecting PCNA in
archival study materials also have been reported (23),
suggesting use in retrospective cell proliferation analy-
sis ofpreviously studied material. PCNA analysis also
has potential to identify the specific cell populations
(G1, S, G2, M) that exist in the cell cycle and the pool of
active proliferating cells; however, more characteriza-
tion studies will be required for this purpose (22). If
feasible, PCNA analysis may lead to quantitation of a
chemical's effect on cell population in different stages
of the cell cycle, yielding potentially critical informa-
tion in understanding chemically induced cell prolifera-
tion. The relationship between PCNA analysis of pro-
liferation to S-phase analysis as measured by other
means have revealed both strong and poor correlations
(24). In some cases more PCNA immunoreactivity was
observed than would be expected as judged by other
markers of proliferation. Although the reason for this
is unknown, it may be related to PCNA message sta-
bility, differences between antibodies used, regulation
of PCNA expression by growth factors, and/or mask-
ing of PCNA antigenic determinants. At present, the
use and proper interpretation of the cell proliferation
response as detected by PCNA analysis requires addi-
tional studies for clarification and validation.
Labeling Study Designs
An important issue in the design of experimental
studies for measuring LI is determining how and when
to investigate the induced proliferative response in
relation to the chemical treatment regimen (15). The
DNA-precursor label for detecting cells in S phase
may be administered either by a single pulse injection
or continuously for several days via an implanted
osmotic pump. The pulse-labeling method gives an
indication of the proliferation at a particular point in
time. Continuous labeling detects all cells that were in
S phase during the period that the pump is in place.
The decision to use the pulse or pump label administra-
tion in a cell replication study depends on the experi-
mental objective and the turnover rate of the target
cell population. For example, it would be inappropriate
to use a 6-day pump to assess increased chemically
induced cell proliferation in the crypts of the small
intestine because all cells would be labeled in the con-
trol group (Goldsworthy, unpublished observation). A
critical issue in using pulse-label techniques to mea-
sure LI is knowing when to sacrifice animals in rela-
tion to chemical treatment. A study design using mul-
tiple sacrifice times with prior pulse dosing is required
to identify a relatively short time course in the induc-
tion of cell proliferation and is the method of choice
when determining the time course and shape ofthe cell
proliferation curve immediately after partial hep-
atectomy or chemical exposure. For evaluating the
magnitude of replication in a target cell population
with a relatively slow turnover rate (i.e., liver, kidney),
to minimize diurnal variations, and to provide a
greater window of time to detect a proliferative
response, the pump-labeling procedure appears to be
the method ofchoice (15,25).
In addition to issues of label administration and
methodology, there are a number ofother critical vari-
ables that must be addressed in the design of studies
investigating cell proliferation. These factors include
treatment regimen, route and dose of chemical expo-
sure, species, strain, sex, age, diurnal variation, diet,
environment, target cell population, method of quanti-
tation, and statistical approaches. All of these factors
may directly or indirectly impact on cell proliferation
data accumulation and interpretation. For this reason,
it is necessary to duplicate bioassay conditions in stud-
ies that attempt to correlate chemically induced cell
proliferation to carcinogenic activity. For example,
when evaluating the hepatic proliferation response to
the hepatocarcinogens dichlorobenzene (DCB) and
furan, we chose the same doses, dosing regimen, ani-
mal species, and experimental conditions that pro-
duced tumors in the rodent cancer bioassay (26,27).
The response seen with cytotoxicant agent furan (Fig.
2) and the mitogenic agent DCB (Fig. 3) are shown as
examples of retrospective studies to determine the
relationship of target tissue proliferation with chemi-
cally induced hepatocarcinogenic activity. Experience
with studies to date have demonstrated the impor-
tance in evaluating a dose, sex, or species that did not
develop tumor formation in order to strengthen or
weaken the linkage between the observed proliferative
response and cancer activity.
Dose Selection Consideration for
Rodent Carcinogenicity Studies
Dose selection is one ofthe most important and con-
troversial considerations in the design of long-term
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FIGURE 2. Furan-induced hepatocyte cell proliferation. Labeling
index in male mice treated for 1, 3, or 6 weeks with the hepatotox-
ic chemical furan (15 mg/kg body weight) or vehicle (corn oil)
under bioassay conditions. Labeling was done with 1 mCi/mL 3H-
TdR administered at 1 pL/hr via an osmotic pump implanted 6
days before necropsy. *Chemical treatment differed significantly
from control (Student-Neuman-Keuls' test, p < 0.05). Redrawn
from Wilson et al. (27).
chemical carcinogenesis experiments. With so few ani-
mals/dose groups in a bioassay, studies to detect
potential carcinogens are frequently designed to
include the highest dose of test compound that can be
predicted not to alter the animals' longevity from
effects other than carcinogenicity (28). This dose is
referred to as the maximum tolerated dose (MTD).
This dose should not cause life-shortening toxicity or
more than a 10% decrease in body weight gain.
Because MTD determination is typically based on data
from prechronic studies, rarely is the optimal expo-
sure level precisely identified (29). It is important to
avoid, or at least be aware of, situations where high
doses of the test chemical compromise the health of
animals, overwhelm natural detoxification mecha-
nisms, or yield tumors secondary to excessive organ-
specific toxicity. Bioassays are faulted and often
required to be repeated at higher doses if no toxicity
is seen in the study. Approximately half of the com-
pounds tested by the National Toxicology Program at
the MTD are carcinogenic in rodents. Some have
raised the concern that many ofthese responses could
be secondary to organ-specific toxicity seen only in
the MTD and question the relevance ofthese observa-
tions for predicting carcinogenicity in people at lower
levels ofexposure (30).
Gathering chemically induced cell proliferation data
as part of the 90-day study that precedes a cancer
bioassay could provide valuable information to aid in
the rational selection ofboth the higher and low doses
for long-term studies (31). Furthermore, this informa-
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FIGURE 3. Dichlorobenzene-induced hepatocyte cell proliferation.
Labeling index in male mice treated for 1, 6, and 13 weeks with
the mitogenic chemical dichlorobenzene (600 mg/kg, filled bars;
300 mg/kg, hatched bars) or vehicle control (corn oil, open bars)
under bioassay conditions. Labeling was done with 20 mg/mL
BrdU administered at 1 pL/hr via an osmotic pump implanted 3
days before necropsy. *Chemical treatment differed significantly
from respective control (Student-Neuman-Keuls' test, p < 0.05).
Redrawn from Eldridge et al. (26).
tion might aid in interpreting bioassay results. If one
biological property of a chemical to be tested is the
induction ofcell proliferation, then the shape ofthe cell
proliferation dose-response curve in a target cell popu-
lation should be one consideration in setting the MTD.
Because dose-response curves for a variety of chemi-
cally induced alterations (i.e. mutations, proliferation,
cell differentiation, gene expression) would be expect-
ed to differ from one another, it is essential to inte-
grate all relevant data in selecting the appropriate
dosages. It is suggested that selection of at least one
dose that does not induce a significant increase in sus-
tained cell proliferation may greatly aid in the inter-
pretation ofthe results ofthe bioassay.
Tissues from 90-day studies should be saved in an
appropriate manner for retrospective evaluation of
proliferative effects at different chemical exposure lev-
els. Including 1 and 3 week groups in addition to 90
days would also be valuable, and may be especially
critical when the identification of the target tissue is
unknown. Prospective and/or retrospective cell prolif-
eration data may be especially valuable for the
nongenotoxicants that induce tumors only when there
is chemically induced cytotolethality and sustained
regenerative cell proliferation.
Research Approaches and Future
Needs
Many ofthe current research efforts to better under-
stand the complex relationships between cell prolifera-
-
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tion and carcinogenic activity focus on early tissue
proliferative responses. Currently, the relationship
between early target tissue proliferation and cancer
induction is unclear. A chemical may induce only a
short-term alteration in cell proliferation or induce cell
proliferation in non-susceptible cells in the target tis-
sue; neither process may be linked to an increased
tumor incidence. In addition, proliferative effects early
in treatment may not reflect the activity observed
after chronic treatment or the proliferative responses
within preneoplastic lesions. Thus it cannot be conclud-
ed that an early cell proliferative result will equate to
an increased risk of cancer. The subacute correlation
approach represents a means to identify agents that
may be increasing tumor formation through enhanced
cell proliferation. Additional data are needed to help
clarify the relationship of chemically induced cell pro-
liferation and carcinogenicity.
Investigation of cell-specific proliferation effects
through the carcinogenic process is needed to further
establish the importance of this end point in chemical
carcinogenesis. Quantitation of chemically induced cell
proliferation effects is currently available for a limited
number of agents. Standard protocols and methodolo-
gies for design and measurement ofchemically induced
cell proliferation are necessary to generate data that
may be formulated into a cohesive database. This data-
base will be required to relate the extent, duration,
and nature of chemically induced cell proliferation to
carcinogenic activity. Cell loss rates must also be stud-
ied in conjunction with cell proliferation to accurately
determine growth rates of the target cell population.
Risk models incorporating cell proliferation data
require quantitation of chemicals' effects on the
growth and loss of specified target populations as well
as the kinetics of those responses. Most important for
improved cancer risk assessment is the identification
ofthe mechanism for the chemically induced prolifera-
tive responses. Retrospective analysis ofcell prolifera-
tion and genetic changes in previous studies, coupled
with increased mechanistic information from cancer
bioassays will yield critical information on the role of
chemically induced cell proliferation in the carcino-
genic process. Future studies need to investigate mito-
genic and cytotoxic induction of differential toxicity
and/or growth stimulation mechanisms that may pro-
vide a preferential growth advantage to spontaneous
or chemically induced precancerous or malignant cells.
Cell proliferative responses must be studied in con-
junction with oncogene and growth factor expression
and mutations, tissue injury and adaption, enzyme
induction, and other parameters to ultimately under-
stand complex relationships between cell proliferation
and carcinogenesis. Information on the role of chemi-
cally induced cell proliferation throughout the cancer
process will be valuable in investigations of mecha-
nisms of carcinogenesis, development of assays for
nongenotoxic carcinogenic activity, and selection of
appropriate risk models.
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